Lutz B Giebel

Title: Lutz B Giebel: Innovator in Therapeutic Proteins

Introduction

Lutz B Giebel is a notable inventor based in San Mateo, California. He has made significant contributions to the field of therapeutic proteins, holding a total of four patents. His work focuses on innovative solutions that enhance medical treatments and improve patient outcomes.

Latest Patents

Among his latest patents are the Single-chain TNF Receptor 2 agonist fusion proteins. This invention provides a fusion protein between a single chain TNFR2 Selective Agonist protein and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety offers therapeutic activity by selectively activating the TNFR2 form of the TNF-α receptor. This selective activation stimulates Tregs and increases myelin deposition, showcasing the potential for significant therapeutic benefits.

Career Highlights

Lutz has worked with several companies throughout his career, including Relinia, Inc. and Axys Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of therapeutic proteins.

Collaborations

Lutz has collaborated with notable professionals in his field, including David C Foster and Leonard G Presta. These collaborations have contributed to the advancement of his research and the successful development of his inventions.

Conclusion

Lutz B Giebel is a distinguished inventor whose work in therapeutic proteins has the potential to transform medical treatments. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.